Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 confirmatory trial of MAT2203 (administered with 5FC) with a control arm of IV amphotericin (also administered with 5-FC) as induction and then consolidation therapy in HIV patients with cryptococcal meningitis

Trial Profile

Phase 3 confirmatory trial of MAT2203 (administered with 5FC) with a control arm of IV amphotericin (also administered with 5-FC) as induction and then consolidation therapy in HIV patients with cryptococcal meningitis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amphotericin B (Primary) ; Amphotericin B (Primary) ; Flucytosine
  • Indications Cryptococcal meningitis
  • Focus Adverse reactions
  • Sponsors Matinas BioPharma

Most Recent Events

  • 20 May 2022 New trial record
  • 12 May 2022 According to a Matinas Biopharma media release, the company plans to meet with FDA in the third quarter of 2022 to finalize the trial design and anticipates that the pivotal Phase 3 registration trial will commence later in 2022, with the anticipated financial support of the National Institutes of Health.
  • 12 May 2022 According to a Matinas Biopharma media release, data from this study will support single NDA filing for both induction and consolidation treatment with MAT2203 in patients with cryptococcal meningitis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top